Zimmer Biomet announced U.S. FDA 510(k) clearance of the ROSA Shoulder System for robotic-assisted shoulder replacement surgery. ROSA Shoulder is the world’s first robotic surgery system for shoulder replacement, and the fourth application for the company’s comprehensive ROSA Robotics portfolio, which includes the ROSA Knee System for total knee arthroplasty and ROSA Hip System for total hip replacement. ROSA Shoulder will be commercially available in the U.S. in the second half of 2024, and will work with the mymobility Digital Care Management Platform to bolster the ZBEdge Dynamic Intelligence portfolio for patients undergoing shoulder replacement surgery.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ZBH:
- BTIG medical technology analyst to hold analyst/industry conference call
- Zimmer Biomet Announces Quarterly Dividend for First Quarter of 2024
- Zimmer Biomet signs Global Health Equity Network’s Zero Health Gaps Pledge
- Zimmer Biomet price target raised to $130 from $120 at Barclays
- Zimmer Biomet price target lowered to $140 from $147 at Deutsche Bank
